|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SRRT |
Gene summary for SRRT |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SRRT | Gene ID | 51593 |
| Gene name | serrate, RNA effector molecule | |
| Gene Alias | ARS2 | |
| Cytomap | 7q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9BXP5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51593 | SRRT | C38 | Human | Oral cavity | OSCC | 7.11e-06 | 1.07e+00 | 0.172 |
| 51593 | SRRT | C43 | Human | Oral cavity | OSCC | 3.06e-16 | 3.70e-01 | 0.1704 |
| 51593 | SRRT | C46 | Human | Oral cavity | OSCC | 5.89e-26 | 6.29e-01 | 0.1673 |
| 51593 | SRRT | C51 | Human | Oral cavity | OSCC | 5.82e-14 | 7.56e-01 | 0.2674 |
| 51593 | SRRT | C57 | Human | Oral cavity | OSCC | 2.42e-11 | 4.74e-01 | 0.1679 |
| 51593 | SRRT | C07 | Human | Oral cavity | OSCC | 9.73e-03 | 6.41e-01 | 0.2491 |
| 51593 | SRRT | C08 | Human | Oral cavity | OSCC | 4.56e-20 | 5.08e-01 | 0.1919 |
| 51593 | SRRT | C09 | Human | Oral cavity | OSCC | 2.91e-08 | 3.37e-01 | 0.1431 |
| 51593 | SRRT | LN22 | Human | Oral cavity | OSCC | 2.75e-09 | 1.05e+00 | 0.1733 |
| 51593 | SRRT | LN46 | Human | Oral cavity | OSCC | 1.94e-10 | 4.49e-01 | 0.1666 |
| 51593 | SRRT | EOLP-1 | Human | Oral cavity | EOLP | 2.79e-04 | 1.57e-01 | -0.0202 |
| 51593 | SRRT | NEOLP-2 | Human | Oral cavity | NEOLP | 2.30e-02 | 8.88e-02 | -0.0196 |
| 51593 | SRRT | NEOLP-3 | Human | Oral cavity | NEOLP | 6.49e-06 | 2.00e-01 | -0.0191 |
| 51593 | SRRT | SYSMH2 | Human | Oral cavity | OSCC | 2.85e-12 | 4.24e-01 | 0.2326 |
| 51593 | SRRT | SYSMH3 | Human | Oral cavity | OSCC | 1.63e-17 | 4.66e-01 | 0.2442 |
| 51593 | SRRT | SYSMH5 | Human | Oral cavity | OSCC | 6.74e-08 | 2.03e-01 | 0.0647 |
| 51593 | SRRT | SYSMH6 | Human | Oral cavity | OSCC | 2.51e-03 | 1.24e-01 | 0.1275 |
| 51593 | SRRT | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 5.50e-03 | 2.96e-01 | -0.1833 |
| 51593 | SRRT | Dong_P1 | Human | Prostate | Tumor | 1.66e-08 | 3.27e-02 | 0.035 |
| 51593 | SRRT | Dong_P3 | Human | Prostate | Tumor | 3.23e-06 | 1.15e-01 | 0.0278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003447010 | Esophagus | HGIN | ncRNA processing | 97/2587 | 395/18723 | 5.92e-09 | 3.90e-07 | 97 |
| GO:00198277 | Esophagus | HGIN | stem cell population maintenance | 39/2587 | 131/18723 | 1.63e-06 | 6.14e-05 | 39 |
| GO:00346606 | Esophagus | HGIN | ncRNA metabolic process | 104/2587 | 485/18723 | 2.26e-06 | 8.23e-05 | 104 |
| GO:00987278 | Esophagus | HGIN | maintenance of cell number | 39/2587 | 134/18723 | 3.02e-06 | 1.03e-04 | 39 |
| GO:00466859 | Esophagus | HGIN | response to arsenic-containing substance | 15/2587 | 33/18723 | 1.08e-05 | 3.10e-04 | 15 |
| GO:00310532 | Esophagus | HGIN | primary miRNA processing | 6/2587 | 13/18723 | 4.97e-03 | 4.18e-02 | 6 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:004668514 | Esophagus | ESCC | response to arsenic-containing substance | 30/8552 | 33/18723 | 5.73e-08 | 1.02e-06 | 30 |
| GO:009872714 | Esophagus | ESCC | maintenance of cell number | 90/8552 | 134/18723 | 3.94e-07 | 5.43e-06 | 90 |
| GO:001982714 | Esophagus | ESCC | stem cell population maintenance | 88/8552 | 131/18723 | 5.23e-07 | 6.97e-06 | 88 |
| GO:001072010 | Esophagus | ESCC | positive regulation of cell development | 172/8552 | 298/18723 | 1.74e-05 | 1.55e-04 | 172 |
| GO:005076710 | Esophagus | ESCC | regulation of neurogenesis | 203/8552 | 364/18723 | 6.10e-05 | 4.68e-04 | 203 |
| GO:00507697 | Esophagus | ESCC | positive regulation of neurogenesis | 131/8552 | 225/18723 | 9.71e-05 | 6.90e-04 | 131 |
| GO:00351969 | Esophagus | ESCC | production of miRNAs involved in gene silencing by miRNA | 37/8552 | 52/18723 | 1.75e-04 | 1.14e-03 | 37 |
| GO:00310508 | Esophagus | ESCC | dsRNA processing | 38/8552 | 54/18723 | 2.08e-04 | 1.31e-03 | 38 |
| GO:00709188 | Esophagus | ESCC | production of small RNA involved in gene silencing by RNA | 38/8552 | 54/18723 | 2.08e-04 | 1.31e-03 | 38 |
| GO:00519606 | Esophagus | ESCC | regulation of nervous system development | 237/8552 | 443/18723 | 5.02e-04 | 2.78e-03 | 237 |
| GO:00519625 | Esophagus | ESCC | positive regulation of nervous system development | 149/8552 | 272/18723 | 1.50e-03 | 7.06e-03 | 149 |
| GO:003105311 | Esophagus | ESCC | primary miRNA processing | 11/8552 | 13/18723 | 4.76e-03 | 1.85e-02 | 11 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SRRT | SNV | Missense_Mutation | c.367A>T | p.Met123Leu | p.M123L | Q9BXP5 | protein_coding | tolerated(0.73) | benign(0) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| SRRT | SNV | Missense_Mutation | c.2546N>G | p.Pro849Arg | p.P849R | Q9BXP5 | protein_coding | tolerated(0.15) | benign(0.151) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| SRRT | SNV | Missense_Mutation | c.2467C>T | p.Pro823Ser | p.P823S | Q9BXP5 | protein_coding | tolerated(0.08) | benign(0.157) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| SRRT | SNV | Missense_Mutation | rs201528871 | c.1801N>T | p.Arg601Trp | p.R601W | Q9BXP5 | protein_coding | deleterious(0) | possibly_damaging(0.544) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| SRRT | SNV | Missense_Mutation | novel | c.456N>G | p.Phe152Leu | p.F152L | Q9BXP5 | protein_coding | tolerated(0.38) | probably_damaging(0.973) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SRRT | SNV | Missense_Mutation | rs199528372 | c.2242N>A | p.Ala748Thr | p.A748T | Q9BXP5 | protein_coding | tolerated(0.36) | benign(0.041) | TCGA-E9-A22H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| SRRT | insertion | Frame_Shift_Ins | novel | c.800_801insATCCC | p.Leu268SerfsTer30 | p.L268Sfs*30 | Q9BXP5 | protein_coding | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| SRRT | SNV | Missense_Mutation | c.118N>A | p.Asp40Asn | p.D40N | Q9BXP5 | protein_coding | deleterious(0.05) | benign(0.227) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| SRRT | SNV | Missense_Mutation | c.2230N>G | p.Lys744Glu | p.K744E | Q9BXP5 | protein_coding | tolerated(0.05) | possibly_damaging(0.85) | TCGA-C5-A1M6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| SRRT | SNV | Missense_Mutation | c.2594G>A | p.Arg865Gln | p.R865Q | Q9BXP5 | protein_coding | deleterious(0.01) | probably_damaging(0.953) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |